RJF vs XFOR · rev $15.91B vs rev $4.8M
RJF (RJF) versus X4 Pharmaceuticals Inc (XFOR) — a side-by-side from cached financials, not a winner call.
RJF (RJF) common stock.
X4 Pharmaceuticals Inc (XFOR) is a biotechnology company listed on NASDAQ.
Latest reported RJF revenue for 2025-09-30 was $15.91B. Net income was $2.13B. Revenue was up 6.6% from 2024-09-30 to 2025-09-30. RJF currently screens at market cap $0.
Latest reported XFOR revenue for 2026-06-30 was $4.8M. Net income was -$36.4M. Revenue was up 92.0% from 2026-03-31 to 2026-06-30. XFOR currently screens at market cap $382.0M.
RJF currently screens at market cap $0. XFOR currently screens at market cap $382.0M.
Not investment advice. Open the RJF and XFOR stock pages for the full models.
Not investment advice.